510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date 510k summary prepared: June 11, 2014

Submitter's Name, address, telephone number, a contact person:

Submitter's Name:

Rayence Co., Ltd.

Submitter's Address:

14, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do, Korea

Submitter's Telephone:

+82-31-8015-6459

Contact person:

Mr. Kee Dock Kim / Manager / +82-31-8015-6459

Official Correspondent:

Dave Kim (davekim@mtech-inc.net)

(U.S. Designated agent)

Address:

8310 Buffalo Speedway, Houston, TX 77025

Telephone:

+713-467-2607

Fax:

+713-583-8988

Name of the device, including the trade or proprietary name if applicable, the common or usual name and the classification name, if known:

Trade/proprietary name:

1417WCC

Common Name:

Digital Flat Panel X-ray Detector

Classification Name:

21CFR892.1680 / Stationary x-ray system

Product Code:

MQB

Predicate Device:

Manufacturer

: Rayence Co., Ltd.

Device

: 1417WCA

510(k) Number

: K130935 (Decision Date - July 2, 2013)

Device Description:

1417WCC is a wired/wireless digital solid state X-ray detector that is based on flat-panel technology. The wireless LAN(IEEE 802.11a/g/n) communication signals images captured to the system and improves the user operability through high-speed processing. This radiographic image detector and processing unit consists of a scintillator coupled to an a-Si TFT sensor. This device needs to be integrated with a radiographic imaging system. It can be utilized to capture and digitalize X-ray images for radiographic diagnosis The RAW files can be further processed as DICOM compatible image files by separate console SW (not part of this 510k submission) for a radiographic diagnosis and analysis.

Indication for use:

1417WCC Digital Flat Panel X-Ray Detector is indicated for digital imaging solution designed for general radiographic system for human anatomy. It is intended to replace film or screen based radiographic systems in all general purpose diagnostic procedures. Not to be used for mammography.

1. Summary of Design Control Risk management

The 1417WCC digital X-ray detector is a modification of 1417WCA (K130935). The new device is designed with a thinner and lighter body compared to its predecessor, 1417WCA. The battery of 1417WCA was attached on the back of the device but the newly designed/1417WGC device has its battery inserted inside the new device.

In addition, a dedicated power supply (model name: RP003A) for [1417WGC is developed and added to its component list. (Optional user selection).


The risks and the hazardous impact of the device modification were analyzed with FMEA method. The specific risk control and protective measures to mitigate the risks from the modification were reviewed and implemented in the new product design phase. The overall assessment concluded that all risks and hazardous conditions identified arising from the design change were successfully mitigated and accepted.


2. Summary of the technological characteristics of the device compared to the predicate device:

The 1417WCC SSXI detector described in this 510(k) has the same indications for use and similar technical characteristics as its predicate device, 1417WCA flat panel detector, of Rayence Co., Ltd.

2.1 Detector

The mechanical design for each device is different as following.





2.2 Power supply

1417WCC requires power supply (Model Name: RP003A)

	1417WCC	1417WCA
Model Name	RP003A	
	(2) LAN (3) 00 (4) POWER	The power supply unit is not provided from Rayence.
	 Power plug connector: Connect with AC power supply cord LAN connector: Ethernet port for transmitting the image/command between detector and PC Link cable connector: Power connector 	
	for detector operating 4 LED indicator: Four LEDs to display the status *Changeable part: Fuse T3.15 AL 250V	
Manufacturer	Rayence Co., Ltd.	

188 X 92 X 41.5 mm			
0.46 kg			
Input rate: 100 ~ 240VAC (50/60Hz) Output: Typ. 24VDC (Max 1.6A)			
		Min	Max
	Voltage	18V	24V
	Current	1.9A	-
	0.46 kg Input rate: 100 ~ 240VAC (50/60Hz)	0.46 kg * Use C approve Input rate : 100 ~ 240VAC (50/60Hz) Output : Typ. 24VDC (Max 1.6A) Voltage	0.46 kg * Use CE or Ulapproved prod Input rate: 100 ~ 240VAC (50/60Hz) Output: Typ. 24VDC (Max 1.6A) Voltage 18V

The 1417WCC flat panel detector is equipped with a dedicated power supply (Model Name: RP003A). The electromagnetic compatibility test for the new device with the power supply has been conducted and the test report is included in this submission. The risk factors associated with the power supply such as power overload and overheating have been assessed and control measures to mitigate risks are discussed.

2.3 A/D conversion (analog-to-digital conversion)

The detector displays an image by digitizing and recording DN value of the analog electrical signal measured. The predicate device used 14 bit series to represent 16,384 values on the gray scale whereas the newly improved subject device is capable of processing both 14 and 16 bit (65,536 gray scale values) series based on the user needs and market requirements.

Characteristic	Proposed Rayence Co.,Ltd. 1417WCC	Predicate Rayence Co.,Ltd. 1417WCA
A/D conversion	14 / 16 bit	14 bit

2.4 Recommended Generator Specification

Model	Manufacture	Specification			
			32kW	40kW	50kW
CMP 200	Communications & Power Industries kVp 40-125	125	40-150		
		mA	10-400	10-500	10-630
EDITOR HFe 501	Rontgenwerk Bochum	kVp		40-150	

1		mA	10-630
-		kVp	40-150
UD150L-40E/40F	Shimadzu	mA	@100 kVp- 500(320)
			@80 kVp- 630(400)
PXR-321B	Dooksom Co. Ltd.	kVp	125/150
	Poskom Co.,Ltd.	mA	500

Note: To our best knowledge, the 1417WGC detector is compatible with the X-ray generators with the specifications described above. For any questions regarding the compatibility issue for other generators which are not listed above, please contact Rayence representative.

3. Proposed Labeling- Changes in comparison to the predicate device

Item	Difference	1417WCC	1417WCA
Devi ce Labe	Detector	SANSFACT RE Payence Co. Let. d. Sumbles from the Management (Section of Section of Sect	METOTOTICE METOTO
	Power Supply	MANUFACTURER Rayence Co., Ltd 14, Samsung 1-to 1-gil, Hwaseong-si, Geonogil-do, Korea www.rayence.com Model: RP003A Product Name: Power Supply SN SN: DATE: Input: AC 100 - 240 V – 50/60Hz, 1.0 - 0.5 A Outgot: 24V-w1/1.60A Caution: Use only with fuses	· ,
Man ual	Indication s for Use	1417WCC Digital Flat Panel X- Ray Detector is indicated for digital imaging solution designed for general radiographic system for human anatomy. It is intended to replace film or screen based radiographic systems in all general purpose diagnostic procedures. Not to be used for mammography.	1417WCA Digital Flat Panel X-Ray Detector is indicated for digital imaging solution designed for general radiographic system for human anatomy. It is intended to replace film or screen based radiographic systems in all general purpose diagnostic procedures. Not to be used for mammography.
	Product	(page 25)	(page 25)

	Specificati	Pixel matrix: 3328 x 2816	Pixel matrix: 3328 x 2816
	on	Pixel area (active): 415 x 350 mm	Pixel area (active): 415 x 350 mm
		Dimensions : 460 x 384 x 15.4	Dimensions: 460 x 417 x 15.9
		mm	mm
İ		Weight: 3.1 kg	Weight: 3.9 kg
_	Standard	802.11a/g/n compliance	802.11a/g/n compliance
Wire	Peak Rate	300Mbps	300Mbps
less	Frequency	2.4 GHz / 5 GHz	2.4 GHz / 5 GHz
Spec	Bandwidth	20MHz/40MHz	20MHz/40MHz
	MIMO	2x2	2x2

4. Summary of Performance Testing

The 1417WCC flat panel detector is a modified version of 1417WCA (K130935), FDA cleared predicate device from Rayence. Indications for use, material, form factor, performance, and safety characteristics between 1417WCC and 1417WCA are identical.

The non-clinical test report and clinical consideration report were prepared and submitted to FDA separately to demonstrate the substantial equivalency between two similar detectors. The non-clinical test report contains the MTF, DQE and NPS test results of 1417WCC and 1417WCA by using the identical test equipment and same analysis method described by IEC 62220-1. The comparison of the MTF for 1417WCC

and 1417WCA detector demonstrated that the MTF of the 1417WCA detector performed almost same with 1417WCC. Therefore, the overall resolution performance and sharpness of 1417WCC is almost same with 1417WCA. The DQE represents the ability to visualize object details of a certain size and contrast. 1417WCC demonstrated higher DQE performance than 1417WCA at various spatial frequencies and provides almost same Signal-to Noise Ratio (SNR) transfer from the input to the output of a detector as a function of frequency. At the lowest spatial frequency, 1417WCC has a DQE of 74% and that of 1417WCA is 72%. 1417WCC also exhibited NPS which has almost same performance with 1417WCA. Therefore, the image quality of 1417WCC is found to be substantially equivalent to 1417WCA at the same patient exposure.

To further demonstrate the substantial equivalency of two devices, clinical images are taken from both devices and reviewed by a licensed US radiologist to render an expert opinion. Both the test subject (1417WCC) and control group (1417WCA) are evaluated and compared by taking sample radiographs of similar age groups and anatomical structures in accordance with the test protocol of diagnostic radiography evaluation procedure.

Based on the non-clinical and clinical consideration test and the outcome of a comparative review by an expert for both devices, we can claim the substantial equivalency between 1417WCC and its predicate device, 1417WCA in terms of image quality.

After comparing a broad review of plain radiographic images taken with the 1417WCC and the 1417WCA, the images obtained with the 1417WCC are comparable or superior to the same view obtained from a similar patient with the 1417WCA. In general, both the spatial resolution and soft tissue contrast are superior using the 1417WCC. Specifically, the soft tissues on extremity films were seen with better clarity. There is no difficulty in evaluating a wide range of anatomic structures necessary to provide a correct conclusion.

The manufacturing facility is in conformance with the design control procedure requirements and the relevant EPRC standards as specified in 21 CFR 802.30 and the records are available for review.

5. Summary for any testing in the submission:

Electrical, mechanical, environmental safety and performance testing according to standard IEC 60601-1: 2005 + CORR.1(2006) + CORR(2007) (Medical electrical equipment Part 1:General requirements for basic safety and essential performance) was performed, and EMC testing were conducted in accordance with standard IEC 60601-1-2:2007.

Non-clinical & Clinical considerations according to FDA Guidance "Guidance for the Submissions of 510(k)'s for Solid State X-ray Imaging Devices" was performed.

All test results were satisfactory.

6. Conclusions:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification Rayence Co., Ltd. concludes that 1417WCC is safe and effective and substantially equivalent in comparison with 1417WCA, the predicate device as described herein.

DEPARTMENT OF HEALTH & HUMAN SERVICES





Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 16, 2014

Rayence Co., Ltd. % Mr. Dave Kim Medical Device Regulatory Affairs 8310 Buffalo Speedway HOUSTON TX 77025

Re: K141566

Trade/Device Name: Solid State X-ray Imaging Device, Digital Flat Panel X-ray Detector,

1417wcc

Regulation Number: 21 CFR 892.1680 Regulation Name: Stationary x-ray system

Regulatory Class: II Product Code: MQB Dated: June 12, 2014 Received: June 16, 2014

Dear Mr. Kim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

fo

Janine M. Morris
Director
Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013 See PRA Statement on last page.

maidations for coo]
510(k) Number <i>(if known)</i> K141566		
Device Name		
417WCC Digital Flat Panel X-Ray Detector		
ndications for Use (Describe)		
1417WCC Digital Flat Panel X-Ray Detector is indicated for digital in numan anatomy. It is intended to replace film or screen based radiography.	maging solution design aphic systems in all ged	ed for general radiographic system for neral purpose diagnostic procedures. Not
		•
Type of Use (Select one or both, as applicable)		
☑ Prescription Use (Part 21 CFR 801 Subpart D)	U Over-The-Coun	iter Use (21 CFR 807 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CO	ONTINUE ON A SEP	ARATE PAGE IF NEEDED.
FOR FDA U		
Concurrence of Center for Devices and Radiological Health (CDRH) (1	
Sm.h.7	ነ)	

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."